CAN NEXVAX2 BE THE ANSWER TO CELIAC DISEASE
Currently, in phase two of clinical trials of Austraila, Nexvax2 could be the change in immune response to gluten. Those intolerant may have an answer to the inflammatory response. If the medicine makes it phase three, approval from the FDA, it can be available to U.S. consumers. Imagine how life-changing this could be for those suffering from celiac disease and are limited by a gluten-free diet.